02 May 2003
Role of PARP activation in the acute respiratory distress syndrome (ARDS)
L. LiaudetMed Sci Monit 2003; 9(1): 35-0 :: ID: 15098
Abstract
The acute respiratory distress syndrome (ARDS) is a severe form of pulmonary inflammation arising as a complication of local (pneumonia, smoke inhalation, aspiration), or systemic (sepsis, trauma, burn injury and pancreatitis) inflammatory processes. The main features of ARDS are diffuse alveolar damage, high permeabiltity pulmonary edema, inflammatory cell infiltration, and loss of surfactant production, resulting in severe disturbances of lung mechanics and gas exchanges. Recent investigations support the concept that activation of PARP, secondary to locally produced oxygen- and nitrogen-derived free radicals and oxidants, may represent a key mechanism of pulmonary inflammation and lung injury in experimental ARDS. In vitro, PARP is activated in response to oxidant-driven DNA damage in respiratory epithelial cells, leading to bioenergetic failure and necrotic cell death [1]. PARP activation also plays a role in the loss of surfactant production by type II pneumocytes exposed to hydrogen peroxide [2]. In vivo, the PARP inhibitor 5-aminoisoquinoline reduced the degree of lung injury and pulmonary neutrophil infiltration in rats challenged by intra-thoracic zymosan-activated plasma, via a mechanism involving a reduced expression of endothelial P-selectin and ICAM-1 [3]. In a murine model of ARDS triggered by the intratracheal instillation of endotoxin, PARP suppression (either by genetic deletion or pharmacological inhibition with PJ-34) markedly reduced the local release of pro-inflammatory cytokines (TNFa, IL-1b and IL-6), and chemokines (MIP-1a and MIP-2), resulting in a lesser degree of neutrophil accumulation and pulmonary edema, as well as in an improved histological status [4]. Thus, oxidant-triggered activation of PARP mediates lung epithelial cell damage and dysfunction, and also represents a central mechanism regulating leukocyte trafficking and the expression of pro-inflammatory mediators within the injured lung. These observations suggest that the pharmacological inhibition of PARP might be useful in clinical conditions associated with overwhelming lung inflammation such as ARDS. References: 1.Nanavaty UB et al: Exp Lung Res, 2002; 28: 591-607 2.Hudak BB et al: Am J Physiol, 1995; 269: L59-64 3.Cuzzocrea S et al: Biochem Pharmacol, 2002; 63: 293-304 4.Liaudet L et al: Am J Respir Crit Care Med, 2002; 165: 372-7
Keywords: Lung, ARDS, PARP, neutrophil
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952